Alzheimer’s disease (AD) is the most common cause of dementia among older adults, and current AD therapies provide only symptomatic relief.

Antioxidants like resveratrol ⁽¹⁾ and vitamin E ⁽²⁾ have been reported to produce significant neuroprotective effects, but their intrinsic instability precludes any relevant, long-lasting form of therapy.

The potent and selective effect of LGA-1623 against lipid peroxidation, together with its excellent metabolic stability, represents a new “clinically validated” strategy to treat AD patients by preventing its worsening.

References
(1) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4626244/
(2) https://www.ncbi.nlm.nih.gov/pubmed/24381967
(3) Selkoe DJ and Hardy J, EMBO Mol Med 2016; 8: 595–608
(4) Liu et al., http://dx.doi.org/10.1016/j.cmet.2017.08.024

For further information about our studies

Ask us

Home - Alzheimer disease

Alzheimer’s disease (AD) is the most common cause of dementia among older adults, and current AD therapies provide only symptomatic relief.

Antioxidants like resveratrol (1) and vitamin E (2) have been reported to produce significant neuroprotective effects, but their intrinsic instability precludes any relevant, long-lasting form of therapy.

For further information about our studies

Antioxidants like resveratrol ⁽¹⁾ and vitamin E ⁽²⁾ have been reported to produce significant neuroprotective effects, but their intrinsic instability precludes any relevant, long-lasting form of therapy.